Lawrence Corey, M.D., president and director of Fred Hutchinson Cancer Research Center, has been honored with the 2012 Cubist-ICAAC Award. An internationally renowned expert in virology, immunology and vaccine development, Corey's research focuses on herpes viruses, HIV, and other viral infections, particularly those associated with cancer. "Corey's work was the first to demonstrate the safety of daily antiviral treatment for immunocompetent persons," explains his nominator, Wesley Van Voorhis of the University of Washington. "His studies led to the routine use of antivirals not only for HSV-2the field he has been the dominant figure in for three decadesbut also HCV, HBV, and HIV."
Corey earned his bachelor's and medical degrees from the University of Michigan, and completed infectious diseases training at the University of Washington School of Medicine. He joined the faculty of the University of Washington in 1978, where he remains today as a Professor of Laboratory Medicine and holder of the Lawrence Corey Endowed Chair in Medical Virology. He is also an infectious disease physician at Seattle Cancer Care Alliance, in addition to his duties as president and director of the Hutchinson Center.
Corey is the principal investigator of the Hutchinson Center-based HIV Vaccine Trials Network (HVTN), an international collaboration of scientists and institutions that combines clinical trials and laboratory-based studies to accelerate the development of HIV vaccines. Under Corey's leadership at the Hutchinson Center, the HVTN has become the model for global collaborative research, involving scientists on four continents and nine countries. "In this capacity, he has overseen the building of a clinical trials network infrastructure from only eight U.S. sites in 1998, to a program that has thirty clinical trial sites in fifteen countries on four continents," explains Anthony S. Fauci, NIAID, NIH. "This network is now at the forefront of clinical trials of
|Contact: Garth Hogan|
American Society for Microbiology